Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE Higher copays associated w/: 💊39% lower odds of HCQ adherence 💊56% lower AZA adherence 💊32% lower MMF adherence Need better $$ and transparency into costs. Screen for determinants of health affecting affordability! @Rheumnow https://t.co/1NdBb3GLzL

There's a lot of Scleroderma-like fibrosing skin disorders! #ACR22 @RheumNow #RheumTwitter @rheumarhyme https://t.co/W1AEtfeKZc

Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls. UCTD and SLE higher disease activity assoc'd w/ dec AMH levels, suggesting dz activity and dz may affect ovarian reserve. Abs 0942 #ACR22 @RheumNow https://t.co/xSZ85ipFSD https://t.co/tsaWBdrQcb

Excllent plenary, medication copay modifies treatment adherence in SLE >$10 copay reduced adherence for HCQ (39%), AZA (56%), MMF (32%) Easy to imagine that all our innovation cannot overcome access & barriers Should be priority to fix #ACR22 @RheumNow #ACRBest Abstr#1115 https://t.co/BPfr9mCVgy

Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of thrombosis relative to progestin-only contraception. Abs 0943 #ACR22 @RheumNow https://t.co/B2Wmhlz6at https://t.co/YlvqoYY8FN

🖊️Eosinophilic fasciitis is not assoc. w/ RP 🖊️On biopsy, extends to SC fat and fascia 🖊️CS are 1st line tx; remission is the rule but takes a while so SLOWLY taper steroids #ACR22 @Rheumnow #RheumTwitter https://t.co/Z26Gim9JUW

Use of pregnancy-compatible medication and control of disease activity with lower glucocorticoid doses in PM/DM pregnancies may be important to achieve good pregnancy outcomes. Abs 0952 #ACR22 @RheumNow https://t.co/LMfebb4GE1 https://t.co/0gYG245BXV

#ACR22 Plenary II Abstr#1114 Access to therapy/Cost need to be improved since high copays (=> 10USD per month) affects adherence to treatment (HCQ, AZA, MMF but not MTX) in #lupus @RheumNow https://t.co/WnwIhpqDxL

Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE? 363 pt P2, double-blind PBO-controlled 48 wk study DEUC 3 mg BID, 6 BID, 12 QB vs PBO: At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk. AEs: similar bw PBO and DEUC. No VTE @RheumNow #ACRBest https://t.co/uamJe05odq

Scleredema has an indolent course Affected skin is doughy Has 3 clinical subgrps: 💠classic adultorum - self-limited, +visceral involvement 💠blood dyscrasia 💠diabetes - visceral involvement is rare #ACR22 @Rheumnow @rheumarhyme https://t.co/ZlQmCc1WYa